Clinical research company IQVIA (NYSE: IQV) announced better-than-expected revenue in Q2 CY2025, with sales up 5.3% year on year to $4.02 billion. The company’s full-year revenue guidance of $16.2 billion at the midpoint came in 0.8% above analysts’ estimates. Its non-GAAP profit of $2.81 per share was 1.4% above analysts’ consensus estimates.
Is now the time to buy IQV? Find out in our full research report (it’s free).
IQVIA (IQV) Q2 CY2025 Highlights:
- Revenue: $4.02 billion vs analyst estimates of $3.97 billion (5.3% year-on-year growth, 1.2% beat)
- Adjusted EPS: $2.81 vs analyst estimates of $2.77 (1.4% beat)
- Adjusted EBITDA: $910 million vs analyst estimates of $905.4 million (22.7% margin, 0.5% beat)
- The company reconfirmed its revenue guidance for the full year of $16.2 billion at the midpoint
- Management slightly raised its full-year Adjusted EPS guidance to $11.90 at the midpoint
- EBITDA guidance for the full year is $3.79 billion at the midpoint, in line with analyst expectations
- Operating Margin: 12.6%, down from 13.6% in the same quarter last year
- Constant Currency Revenue rose 3.6% year on year, in line with the same quarter last year
- Market Capitalization: $31.85 billion
StockStory’s Take
IQVIA’s second quarter results were met with a notably positive market reaction, as the company’s revenue and non-GAAP profit surpassed Wall Street expectations. Management attributed the quarter’s performance to robust growth in its Technology & Analytics Solutions segment, particularly real-world evidence solutions, and an improved win rate in research and development contracts. CEO Ari Bousbib emphasized that clients are resuming drug launches despite a mixed industry backdrop, highlighting, “Clients are continuing to execute in a regular way. They have commercial road maps and those require services.”
Looking ahead, IQVIA’s full-year guidance is underpinned by continued strength in its backlog, accelerated adoption of AI-driven offerings, and a strategy focused on expanding its pipeline of opportunities. Management acknowledged ongoing pricing pressures and margin headwinds due to business mix shifts, but continues to invest in AI agent development and operational efficiency. CFO Ron Bruehlman noted, “We expect internally that those efficiencies will enable us to resume margin expansion and continue to mitigate those pricing pressures we are seeing in the short term.”
Key Insights from Management’s Remarks
Management credited the quarter’s performance to growth in AI-enabled solutions, improved sales execution, and a record R&D backlog, while also addressing margin pressures from mix and currency effects.
- AI-driven client solutions: IQVIA advanced its AI capabilities, launching over 20 specialized agents to streamline operations and accelerate insights for life sciences clients. Collaboration with NVIDIA has enabled rapid development, with agents already reducing project timelines and costs, such as cutting literature review times by two-thirds.
- R&D backlog reaches new highs: The company reported a record R&D Solutions backlog exceeding $32 billion, up more than 5% year-over-year. Growth was driven by higher win rates and increased proposal activity, especially in the emerging biotech segment, where pipeline expansion was strongest.
- Real-world evidence outpaces other segments: Real-world evidence, comprising about one-third of the Technology & Analytics Solutions segment, delivered double-digit growth, offsetting slower trends in consulting and data services. Management pointed to increased demand for data-driven product launches and regulatory support.
- Oncology and obesity trials drive bookings: IQVIA continued to win a significant share of oncology and obesity-related clinical trials, securing new global phase III projects and expanding collaborations with leading research institutions. These wins highlight the company’s expertise in high-growth therapeutic areas.
- Margin pressure from mix and FX: Operating margin declined year-over-year, with management citing a shift toward lower-margin services in both R&D and analytics, as well as foreign exchange effects. About two-thirds of the margin compression was attributed to mix, and one-third to currency, partially offset by cost control measures.
Drivers of Future Performance
IQVIA expects near-term growth to be shaped by robust R&D demand, continued AI investment, and ongoing margin pressures from business mix and pricing.
- Continued AI and digital expansion: Management is prioritizing the rollout of over 50 new AI agents in the coming quarter, aiming to increase operational efficiency and client value. IQVIA believes these initiatives will support faster project delivery and help mitigate future margin compression.
- Strength in late-stage clinical trials: The company anticipates that ongoing momentum in oncology and obesity trials, along with the resumption of previously delayed studies, will drive revenue growth in the second half and into next year. A significant uptick in requests for proposals (RFPs) and a growing qualified pipeline serve as forward indicators.
- Margin headwinds likely to persist: CFO Ron Bruehlman cautioned that unfavorable mix—such as higher contributions from lower-margin services and real-world evidence—combined with competitive pricing, will continue to weigh on margins in the near term, though efficiency gains from AI and cost discipline could provide partial relief.
Catalysts in Upcoming Quarters
In the coming quarters, the StockStory team will be watching (1) execution and client uptake of new AI-driven solutions, (2) growth in the R&D Solutions backlog and actual conversion of pipeline into revenue, and (3) the trend of operating margins as IQVIA balances pricing, business mix, and continued investment in technology. Progress in high-growth therapeutic areas such as oncology and obesity trials will also be crucial markers.
IQVIA currently trades at $190, up from $158.91 just before the earnings. At this price, is it a buy or sell? See for yourself in our full research report (it’s free).
Now Could Be The Perfect Time To Invest In These Stocks
Trump’s April 2024 tariff bombshell triggered a massive market selloff, but stocks have since staged an impressive recovery, leaving those who panic sold on the sidelines.
Take advantage of the rebound by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.